Bayer Loses Patent Fight Over Cancer Drug

By Admin
Pharmaceutical giant Bayer has lost its legal fight to overturn the Indian governments decision to allow Natco Pharma to produce its cancer drug Nexav...


Pharmaceutical giant Bayer has lost its legal fight to overturn the Indian government’s decision to allow Natco Pharma to produce its cancer drug Nexavar under compulsory licence.

The Intellectual Property Appellate Board (IPAB) in Chennai upheld the landmark decision made last March by the comptroller of patents citing the high cost of the medication.

Nexavar is used in the treatment of liver and kidney cancer and was sold by Bayer for Rs.280,000 ($5,100) per month while Natco is selling the drug for only Rs. 6,840 ($125) a month.

Natco will pay Bayer, Germany’s largest pharmaceutical company, a seven percent royalty rate on all the drugs they sell. The percentage was raised from six percent royalties by the IPAB.

“The challenges faced by the Indian healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India’s essential drug list are not patented,” said Bayer. The company has stated that they intend to take the case to the Indian high court.

The compulsory license is recognised by the World Trade Organisation and is a tool used by governments to allow a company to manufacture a patented drug, without the consent of the innovator company.

Under the global Trade-Related Aspects of Intellectual Property Rights agreement, countries can issue these licences on drugs that are deemed unaffordable to a large section of their populations.

Charities working in India were relieved by the decision. Medecins sans Frontieres said, “The decision confirms that the Indian patent office is able to use all the means legally at its disposal to check the abuse of patents and open up access to affordable versions of patented medicines.”


Featured Articles

SpaceX Starlink Launch Boost for Indonesia Healthcare

As SpaceX CEO Elon Musk helps launch new satellite in Indonesia, we look at how the Starlink programme is improving healthcare provision in remote areas

J&J Targets Supplier Sustainability to Cut Healthcare GHGs

Johnson & Johnson takes collaborative approach to tackling the problem of carbon emissions in the global healthcare supply chain

Walgreens to Sell Over-the-Counter Opioid Overdose Drug

As Walgreens launches an own-brand opioid overdose reversal drug, we take a look at the role of naloxone in combatting decades of US opioid deaths

McKinsey Health Institute: Focus on Health Insights Body

Digital Healthcare

AstraZeneca & Celonis Map out Digital Transformation

Technology & AI

Google DeepMind's AlphaFold 3 'is Drug Discovery Boost'

Technology & AI